Endotypes of Chronic Rhinosinusitis Based on Inflammatory and Remodeling Factors
Xiangdong Wang,Yutong Sima,Yan Zhao,Nan Zhang,Ming Zheng,Kun Du,Min Wang,Yue Wang,Yun Hao,Ying Li,Manjiao Liu,Yingshi Piao,Chengyao Liu,Peter Tomassen,Luo Zhang,Claus Bachert
DOI: https://doi.org/10.1016/j.jaci.2022.10.010
2023-01-01
Abstract:Background: Previous studies on the endotyping of chronic rhinosinusitis (CRS) that were based on inflammatory factors have broadened our understanding of the disease. However, the endotype of CRS combined with inflammatory and remodeling features has not yet been clearly elucidated. Objective: We sought to identify the endotypes of patients with CRS according to inflammatory and remodeling factors. Methods: Forty-eight inflammatory and remodeling factors in the nasal mucosal tissues of 128 CRS patients and 24 control subjects from northern China were analyzed by Luminex, ELISA, and ImmunoCAP. Sixteen factors were used to perform the cluster analysis. The characteristics of each cluster were analyzed using correlation analysis and validated by immunofluorescence staining. Results: Patients were classified into 5 clusters. Clusters 1 and 2 showed non-type 2 signatures with low biomarker concentrations, except for IL-19 and IL-27. Cluster 3 involved a low type 2 endotype with the highest expression of neutrophil factors, such as granulocyte colony-stimulating factor, IL-8, and myeloperoxidase, and remodeling factors, such as matrix metalloproteinases and fibronectin. Cluster 4 exhibited moderate type 2 inflammation. Cluster 5 exhibited high type 2 inflammation, which was associated with relatively higher levels of neutrophil and remodeling factors. The proportion of CRS with nasal polyps, asthma, allergies, anosmia, aspirin sensitivity, and the recurrence of CRS increased from clusters 1 to 5. Conclusion: Diverse inflammatory mechanisms result in distinct CRS endotypes and remodeling profiles. The explicit differentiation and accurate description of these endotypes will guide targeted treatment decisions. (J Allergy Clin Immunol 2023;151:458-68.)